References
- Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98–105. doi:https://doi.org/10.1136/heartjnl-2018-313599.
- Naseem R, Adam AM, Khan F, Dossal A, Khan I, Khan A, Paul H, Jawed H, Aslam A, Syed FM, Niazi MA, Nadeem S, Khan A, Zia A, Arshad MH. Prevalence and characteristics of resistant hypertensive patients in an Asian population. Indian Heart J. 2017;69(4):442–46. doi:https://doi.org/10.1016/j.ihj.2017.01.012
- Sinnott SJ, Smeeth L, Williamson E, Douglas IJ. Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995–15. BMJ. 2017;358:j3984. doi:https://doi.org/10.1136/bmj.j3984
- Parreira RC, Lacerda LHG, Vasconcellos R, Lima SS, Santos AK, Fontana V, Sandrim VC, Resende RR. Decoding resistant hypertension signalling pathways. Clin Sci (Lond). 2017;131(23):2813–34. doi:https://doi.org/10.1042/CS20171398
- Saxena T, Ali AO, Saxena M. Pathophysiology of essential hypertension: an update. Expert Rev Cardiovasc Ther. 2018;16(12):879–87. doi:https://doi.org/10.1080/14779072.2018.1540301
- Pugliese NR, Masi S, Taddei S. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Fail Rev. 2020;25(1):31–42. doi:https://doi.org/10.1007/s10741-019-09855-5.
- Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. The Lancet. 2014;383(9917):622–29. doi:https://doi.org/10.1016/s0140-6736(13)62192-3
- Li J, He Q, Li Q, Huang R, Wei X, Pan X, Wu W. Decreased expression of Na(+)-H(+) exchanger isoforms 1 and 3 in denervated spontaneously hypertensive rat kidney. Clin Exp Hypertens. 2019;41(3):235–43. doi:https://doi.org/10.1080/10641963.2018.1469639
- Li J, He Q, Wu W, Li Q, Huang R, Pan X, Lai W. Role of the renal sympathetic nerves in renal sodium/potassium handling and renal damage in spontaneously hypertensive rats. Exp Ther Med. 2016;12(4):2547–53. doi:https://doi.org/10.3892/etm.2016.3669
- Pr S. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol. 1992;19(Suppl 6):S80–S8. doi:https://doi.org/10.1097/00005344-199219006-00013.
- Abdel Ghafar MT. An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension. Steroids. 2020;163:108701. doi:https://doi.org/10.1016/j.steroids.2020.108701.
- Sata Y, Head GA, Denton K, May CN, Schlaich MP. Role of the sympathetic nervous system and its modulation in renal hypertension. Front Med (Lausanne). 2018;5:82. doi:https://doi.org/10.3389/fmed.2018.00082.
- Re RN. Tissue renin angiotensin systems. Medical Clinics of North America. 2004;88(1):19–38. doi:https://doi.org/10.1016/s0025-7125(03)00124-x.
- E. F, C. G, MA. C, B. M, C. SGG. G et al. Comparison of circulating and local adipose tissue reninangiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Invest. 2002;25(4):309–14. doi:https://doi.org/10.1007/BF03344010.
- D. G, K. H, C. B, T. U, RE. L. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science. 1983;221(4613):869–71. doi:https://doi.org/10.1126/science.6879184.
- Cuadra AE, Shan Z, Sumners C, Raizada MK. A current view of brain renin-angiotensin system: is the (pro)renin receptor the missing link? Pharmacol Ther. 2010;125(1):27–38. doi:https://doi.org/10.1016/j.pharmthera.2009.07.007.
- C. K, K. L, M. O, L. S, B. C, LM. C. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab. 1998;83(11):3925–29. doi:https://doi.org/10.1210/jcem.83.11.5276.
- M. P, J. W, VJ. D. Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest. 1993;91(5):2058–64. doi:https://doi.org/10.1172/JCI116428.
- Y. K, T. O, K. M, R. W, K. H. Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. Biochem Biophys Res Commun. 1992;188(1):446–52. doi:https://doi.org/10.1016/0006-291x(92)92405-m.
- Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6(5):261–73. doi:https://doi.org/10.1038/nrneph.2010.30.
- Luther JM. Aldosterone in vascular and metabolic dysfunction. Curr Opin Nephrol Hypertens. 2016;25(1):16–21. doi:https://doi.org/10.1097/MNH.0000000000000189.
- Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251–87. doi:https://doi.org/10.1124/pr.59.3.3.
- Kowalski R, Kreft E, Kasztan M, Jankowski M, Szczepanska-Konkel M. Chronic renal denervation increases renal tubular response to P2X receptor agonists in rats: implication for renal sympathetic nerve ablation. Nephrol Dial Transplant. 2012;27(9):3443–48. doi:https://doi.org/10.1093/ndt/gfs087.
- Coaxum SD, Garnovskaya MN, Gooz M, Baldys A, Raymond JR. Epidermal growth factor activates Na(+/)H(+) exchanger in podocytes through a mechanism that involves Janus kinase and calmodulin. Biochim Biophys Acta. 2009;1793(7):1174–81. doi:https://doi.org/10.1016/j.bbamcr.2009.03.006.
- Shen Z, Weng C, Zhang Z, Wang X, Yang K. Renal sympathetic denervation lowers arterial pressure in canines with obesity-induced hypertension by regulating GAD65 and AT1R expression in rostral ventrolateral medulla. Clin Exp Hypertens. 2018;40(1):49–57. doi:https://doi.org/10.1080/10641963.2017.1306542.
- Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–08. doi:https://doi.org/10.1038/nprot.2008.73.
- Tian D, Shi X, Zhao Y, Peng X, Zou L, Xu L, Ma Y, Wen Y, Faulhaber-Walter R, Chen L. The effect of A1 adenosine receptor in diabetic megalin loss with caspase-1/IL18 signaling. Diabetes Metab Syndr Obes. 2019;12: 1583–96
- Zhou Y, Ren J, Li P, Ma R, Zhou M, Zhang N, Kong X, Hu Z, Xiao X. Expression of urokinase-type plasminogen activator receptor and its soluble form in Type 2 diabetic kidney disease. Arch Med Res. 2019;50(5):249–56. doi:https://doi.org/10.1016/j.arcmed.2019.08.007
- YM P. M. P, D. G. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res. 1998;39(1):77–88. doi:https://doi.org/10.1016/s0008-6363(98)00077-7.
- Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol. 2005;16(7):2073–80. doi:https://doi.org/10.1681/ASN.2004080676.
- Isobe-Sasaki Y, Fukuda M, Ogiyama Y, Sato R, Miura T, Fuwa D, Mizuno M, Matsuoka T, Shibata H, Ito H, Ono M, Abe-Dohmae S, Kiyono K, Yamamoto Y, Kobori H, Michikawa M, Hayano J, Ohte N. Sodium balance, circadian BP rhythm, heart rate variability, and intrarenal renin-angiotensin-aldosterone and dopaminergic systems in acute phase of ARB therapy. Physiol Rep. 2017;5(11):e13309. doi:https://doi.org/10.14814/phy2.13309
- Reina-Couto M, Afonso J, Carvalho J, Morgado L, Ronchi F. A, de Oliveira Leite A. P, Dias C. C, Casarini D. E, Bettencourt P, Albino-Teixeira A, Morato M, Sousa T. Interrelationship between renin-angiotensin-aldosterone system and oxidative stress in chronic heart failure patients with or without renal impairment. Biomed Pharmacother. 2021;133:110938
- Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet. 2017;390(10108):2160–70. doi:https://doi.org/10.1016/s0140-6736(17)32281-x.
- Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2018;391(10137):2346–55. doi:https://doi.org/10.1016/s0140-6736(18)30951-6
- Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, Haskin R, Negoita M, Shimada K. SYMPLICITY HTN-Japan - first randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J. 2015;79(6):1222–29. doi:https://doi.org/10.1253/circj.CJ-15-0150
- Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27. doi:https://doi.org/10.1093/eurheartj/ehu441
- Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–59. doi:https://doi.org/10.1093/eurheartj/ehu209
- Nishiyama A, Kobori H. Independent regulation of renin-angiotensin-aldosterone system in the kidney. Clin Exp Nephrol. 2018;22(6):1231–39. doi:https://doi.org/10.1007/s10157-018-1567-1.
- Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol. 2010;31(6):541–50. doi:https://doi.org/10.1159/000313363.
- Cheng H-F, Becker BN, Bums KD, Hams RC. Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest. 1995;95(5):2012–19.doi:https://doi.org/10.1172/JCI117886.
- Lg N, H. K, M. P-C. Intrarenal angiotensin II and hypertension. Curr Hypertens Rep. 2003;5(2):135–43. doi:https://doi.org/10.1007/s11906-003-0070-5.
- LG. N, LM. H-B. Intrarenal angiotensin II augmentation in angiotensin II dependent hypertension. Hypertens Res. 2000;23(4):291–301. doi:https://doi.org/10.1291/hypres.23.291.
- Benigni A, Cassis P, Angiotensin RG. II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247–57. doi:https://doi.org/10.1002/emmm.201000080.
- Feng Q, Lu C, Wang L, Song L, Li C, Uppada RC. Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infracted dogs. BMC Cardiovasc Disord. 2017;17(1):65. doi:https://doi.org/10.1186/s12872-017-0498-1.
- Tu S, Shen ZJ, Wang XY, Zeng LX, Zhang ZH. Catheter-based radiofrequency renal sympathetic denervation decreases left ventricular hypertrophy in hypertensive dogs. Mediators Inflamm. 2021;2021:9938486. doi:https://doi.org/10.1155/2021/9938486.
- Liang Z, Shi XM, Liu LF, Chen XP, Shan ZL, Lin K, Li J, Chen FK, Li YG, Guo HY, Wang YT. Renal denervation suppresses atrial fibrillation in a model of renal impairment. PLoS One. 2015;10(4):e0124123. doi:https://doi.org/10.1371/journal.pone.0124123
- Lubanda JC, Chochola M, Mlček M, Neužil P, Marek J, Havránek Š, Kuchynková S, Fingrová Z, Huang KA, Linhart A. The effect of renal denervation in an experimental model of chronic renal insufficiency, The REmnant kidney Denervation In Pigs study (REDIP study). J Transl Med. 2017;15(1):215. doi:https://doi.org/10.1186/s12967-017-1319-0
- Bürgelová M, Kramer HJ, Teplan V, Velicková G, Vítko S, Heller J, Malý J, Cervenka L. Intrarenal infusion of angiotensin-(1–7) modulates renal functional responses to exogenous angiotensin II in the rat. Kidney Blood Press Res. 2002;25(4):202–10. doi:https://doi.org/10.1159/000066340
- HF. C, KD. B, RC. H. Reduced proximal tubule angiotensin II receptor expression in streptozotocin-induced diabetes mellitus. Kidney Int. 1994;46(6):1603–10. doi:https://doi.org/10.1038/ki.1994.458.
- RM. E, N. A. Angiotensin II receptor subtypes in the kidney. J Am Soc Nephrol. 1993;3(10):1643–52. doi:https://doi.org/10.1681/ASN.V3101643.
- T. I. Regulation of angiotensin II receptor expression. Curr Pharm Des. 2013;19(17):3013–21. doi:https://doi.org/10.2174/1381612811319170007.
- Pontes RB, Crajoinas RO, Nishi EE, Oliveira-Sales EB, Girardi AC, Campos RR, Bergamaschi CT. Renal nerve stimulation leads to the activation of the Na+/H+ exchanger isoform 3 via angiotensin II type I receptor. Am J Physiol Renal Physiol. 2015;308(8):F848–56. doi:https://doi.org/10.1152/ajprenal.00515.2014
- Hong MN, Li XD, Chen DR, Ruan CC, Xu JZ, Chen J, Wu YJ, Ma Y, Zhu DL, Gao PJ. Renal denervation attenuates aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension. Oncotarget. 2016;7(42):67828–40. doi:https://doi.org/10.18632/oncotarget.12182
- CE. G-S, MY. Z, EN. C, H. M, MF. F, EP. G-S. Aldosterone biosynthesis in the rat brain. Endocrinology. 1997;138(8):3369–73. doi:https://doi.org/10.1210/endo.138.8.5326.
- G-s EP. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology. 1986;118(2):819–23. doi:https://doi.org/10.1210/endo-118-2-819.
- Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol. 2008;294(2):H1067–74. doi:https://doi.org/10.1152/ajpheart.01131.2007.
- Huang BS, White RA, Jeng AY, Leenen FH. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R994–R1000. doi:https://doi.org/10.1152/ajpregu.90903.2008.
- Leenen FH. Actions of circulating angiotensin II and aldosterone in the brain contributing to hypertension. Am J Hypertens. 2014;27(8):1024–32. doi:https://doi.org/10.1093/ajh/hpu066.
- DP. L, SR. C, HL. P. Angiotensin II stimulates spinally projecting paraventricular neurons through presynaptic disinhibition. J Neurosci. 2003;23(12):5041–49. doi:https://doi.org/10.1523/JNEUROSCI.23-12-05041.
- Dupont AG, Brouwers S. Brain angiotensin peptides regulate sympathetic tone and blood pressure. J Hypertens. 2010;28(8):1599–610. doi:https://doi.org/10.1097/HJH.0b013e32833af3b2.
- JW. W, KA. R, LA. S, JM. H, JW. H. Hypothalamic angiotensin release in response to AI1 or glutamic acid stimulation of the SF0 in rats. Brain Res Bull. 1993;31(6):649–54. doi:https://doi.org/10.1016/0361-9230(93)90136-y.
- Gabor A, Leenen FH. Central neuromodulatory pathways regulating sympathetic activity in hypertension. J Appl Physiol (1985). 2012;113(8):1294–303. doi:https://doi.org/10.1152/japplphysiol.00553.2012.
- Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doevendans PA. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J. 2011;19(7–8):319–23. doi:https://doi.org/10.1007/s12471-011-0143-z.
- Ahmed H, Neuzil P, Skoda J, Petru J, Sediva L, Schejbalova M, Reddy VY. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv. 2012;5(7):758–65. doi:https://doi.org/10.1016/j.jcin.2012.01.027
- Ewen S, Cremers B, Meyer MR, Donazzan L, Kindermann I, Ukena C, Helfer AG, Maurer HH, Laufs U, Grassi G, Böhm M, Mahfoud F. Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. J Hypertens. 2015;33(12):2519–25. doi:https://doi.org/10.1097/HJH.0000000000000752
- Ezzahti M, Moelker A, Friesema ECH, van der Linde NAJ, Krestin GP. Van den Meiracker AH. Blood pressure and neurohormonal responses to renal nerve ablation in treatment-resistant hypertension. J Hypertens. 2014;32(1):135–41. doi:https://doi.org/10.1097/HJH.0b013e3283658ef7.
- Mahfoud F, Townsend RR, Kandzari DE, Kario K, Schmieder RE, Tsioufis K, Pocock S, David S, Patel K, Rao A, Walton A, Bloom JE, Weber T, Suppan M, Lauder L, Cohen SA, McKenna P, Fahy M, Böhm M, Weber MA. Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. J Am Coll Cardiol. 2021;77(23):2909–19. doi:https://doi.org/10.1016/j.jacc.2021.04.044
- Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP, May CN. Reinnervation following catheter-based radio-frequency renal denervation. Exp Physiol. 2015;100(5):485–90. doi:https://doi.org/10.1113/expphysiol.2014.079871
- Singh RR, McArdle ZM, Iudica M, Easton LK, Booth LC, May CN, Parkington HC, Lombardo P, Head GA, Lambert G, Moritz KM, Schlaich MP, Denton KM. Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation. Hypertension. 2019;73(3):718–27. doi:https://doi.org/10.1161/HYPERTENSIONAHA.118.12250
- Mulder J, Hokfelt T, Knuepfer MM, Kopp UC. Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol. 2013;304(8):R675–82. doi:https://doi.org/10.1152/ajpregu.00599.2012.
- Rodionova K, Fiedler C, Guenther F, Grouzmann E, Neuhuber W, Fischer MJ, Ott C, Linz P, Freisinger W, Heinlein S, Schmidt ST, Schmieder RE, Amann K, Scrogin K, Veelken R, Ditting T. Complex reinnervation pattern after unilateral renal denervation in rats. Am J Physiol Regul Integr Comp Physiol. 2016;310(9):R806–18. doi:https://doi.org/10.1152/ajpregu.00227.2014
- Dasgupta I, Sharp ASP. Renal sympathetic denervation for treatment of hypertension: where are we now in 2019? Curr Opin Nephrol Hypertens. 2019;28(5):498–506. doi:https://doi.org/10.1097/MNH.0000000000000532.
- Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR, Kario K, Böhm M, Sharp ASP, Davies JE, Osborn JW, Fink GD, Euler DE, Cohen DL, Schlaich MP, Esler MD. Renal denervation for treating hypertension: current scientific and clinical evidence. JACC Cardiovasc Interv. 2019;12(12):1095–105. doi:https://doi.org/10.1016/j.jcin.2019.02.050
- K. M, F. M, R. S, J. D, DE. K, J. W et al. Catheter-based renal sympathetic denervation - long-term symplicity™ renal denervation clinical evidence, new data and future perspectives. Interv Cardiol. 2013;8(2):118–23. doi:https://doi.org/10.15420/icr.2013.8.2.118.
- Akinseye OA, Ralston WF, Johnson KC, Ketron LL, Womack CR, Ibebuogu UN. Renal sympathetic denervation: a comprehensive review. Curr Probl Cardiol. 2021;46(3):100598. doi:https://doi.org/10.1016/j.cpcardiol.2020.100598.
- Atti V, Turagam MK, Garg J, Lakkireddy D. Renal sympathetic denervation improves clinical outcomes in patients undergoing catheter ablation for atrial fibrillation and history of hypertension: a meta-analysis. J Cardiovasc Electrophysiol. 2019;30(5):702–08. doi:https://doi.org/10.1111/jce.13868.
- Elvan A. Antiarrhythmic effects of renal sympathetic denervation in patients with refractory ventricular arrhythmias and structural heart disease. Heart Rhythm. 2020;17(2):228–29. doi:https://doi.org/10.1016/j.hrthm.2019.10.006.